600276 恒瑞医药
交易中 02-27 14:39:49
资讯
新帖
简况
恒瑞医药(01276)2月26日斥资1563.03万元回购27.6万股A股
智通财经 · 02-26 16:20
恒瑞医药(01276)2月26日斥资1563.03万元回购27.6万股A股
【市场】17个国谈药拟进院，独家品种霸屏
米内网 · 02-25 16:07
【市场】17个国谈药拟进院，独家品种霸屏
恒瑞医药(600276.SH)：1类创新药SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序
智通财经 · 02-24 16:44
恒瑞医药(600276.SH)：1类创新药SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序
恒瑞医药：不存在按规定应披露而未披露的重大信息
证券日报 · 02-13
恒瑞医药：不存在按规定应披露而未披露的重大信息
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市
证券日报 · 02-11
恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市
恒瑞医药：公司2025年利润分配方案尚未披露
证券日报 · 02-11
恒瑞医药：公司2025年利润分配方案尚未披露
恒瑞医药(01276)：注射用瑞康曲妥珠单抗上市许可申请获受理并纳入优先审评程序
智通财经 · 02-10
恒瑞医药(01276)：注射用瑞康曲妥珠单抗上市许可申请获受理并纳入优先审评程序
凯莱拉疗法：口服利鲁肽中国二期试验26周平均减重达12.1% 未现平台期
美股速递 · 02-10
凯莱拉疗法：口服利鲁肽中国二期试验26周平均减重达12.1% 未现平台期
恒瑞医药与Kailera Therapeutics公布口服Ribupatide二期肥胖症试验积极顶线数据
美股速递 · 02-10
恒瑞医药与Kailera Therapeutics公布口服Ribupatide二期肥胖症试验积极顶线数据
恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市
智通财经 · 02-06
恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市
恒瑞医药子公司获批SHR-1894注射液临床试验
财中社 · 02-05
恒瑞医药子公司获批SHR-1894注射液临床试验
港股恒瑞医药涨超3%
每日经济新闻 · 02-05
港股恒瑞医药涨超3%
恒瑞医药(01276)2月4日斥资931.7万元回购16.5万股A股
智通财经网 · 02-04
恒瑞医药(01276)2月4日斥资931.7万元回购16.5万股A股
司美格鲁肽年销361亿美元，全球“药王”之战进入下半场
21世纪经济报道 · 02-04
司美格鲁肽年销361亿美元，全球“药王”之战进入下半场
恒瑞医药：公司日常经营管理和业务状况正常
证券日报 · 02-03
恒瑞医药：公司日常经营管理和业务状况正常
恒瑞医药：重新提交注射用卡瑞利珠单抗联合方案获FDA受理
财经网 · 02-03
恒瑞医药：重新提交注射用卡瑞利珠单抗联合方案获FDA受理
恒瑞医药回购979万股 金额6.46亿元
财中社 · 02-02
恒瑞医药回购979万股 金额6.46亿元
恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理
智通财经 · 02-02
恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理
江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划
中金财经 · 01-31
江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":56.7,"timestamp":1772174389000,"preClose":56.72,"halted":0,"volume":29592806,"delay":0,"changeRate":-0.0004,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"交易中","change":-0.02,"latestTime":"02-27 14:39:49","open":56.62,"high":57.27,"low":56.3,"amount":1680000000,"amplitude":0.0171,"askPrice":56.7,"askSize":7,"bidPrice":56.69,"bidSize":21,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772175600000},"marketStatusCode":2,"adr":0,"adjPreClose":56.72,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":62.39,"lowLimit":51.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.33,"roa":"--","peRate":50.391042,"roe":"11.09%","epsLYR":1,"committee":0.385887,"marketValue":376329000000,"turnoverRate":0.0046,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":67.3,"timestamp":1772174387433,"preClose":66,"halted":0,"volume":1909570,"delay":0,"premium":"+3.96"},"floatMarketCap":361689000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2614018284","title":"恒瑞医药(01276)2月26日斥资1563.03万元回购27.6万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2614018284","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614018284?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:20","pubTimestamp":1772094053,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年2月26日斥资1563.03万元回购27.6万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU2328871848.SGD","LU1328615791.USD","LU1997244956.HKD","LU0359202008.SGD","LU2495084118.USD","LU1997245094.SGD","LU1655091616.SGD","LU2580892789.USD","BK1191","LU0405327494.USD","399300","BK0188","LU1580142542.USD","LU2580892862.HKD","LU1064130708.USD","LU0405327148.USD","159982","LU0359201885.HKD","LU1255011170.USD","LU1969619763.USD","BK0028","BK0183","BK0239","LU2148510915.USD","LU1023057109.AUD","LU2488822045.USD","LU2543165471.USD","LU2097828557.USD","LU1820825898.SGD","LU2097828474.EUR","01276","LU2097828631.EUR","BK0196","LU2289578879.USD","LU1997245177.USD","LU2097828805.USD","LU1781817850.SGD","LU0359201612.USD","LU1146622755.USD","BK0060","LU1064131003.USD","600276","LU2097828714.EUR"],"gpt_icon":0},{"id":"2614554709","title":"【市场】17个国谈药拟进院，独家品种霸屏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:07","pubTimestamp":1772006826,"startTime":"0","endTime":"0","summary":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","NVO","BK4532","01276","BK4599","NVOH","BK4585","NVS","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","002793","002653","IE00BZ1G4Q59.USD","NVOX","600276","BK4007","LU1093756168.USD"],"gpt_icon":1},{"id":"2613862796","title":"恒瑞医药(600276.SH)：1类创新药SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2613862796","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613862796?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:44","pubTimestamp":1771922674,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 恒瑞医药 发布公告，近日，公司子公司北京盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司1类创新药SHR-1918注射液的药品上市许可申请获受理，且已被纳入优先审评程序。SHR-1918注射液是公司自主研发的血管生成素样蛋白3单克隆抗体，通过抑制ANGPTL3的活性，从而降低血清中的甘油三酯和LDL-C水平。经查询EvaluatePharma数据库，该产品2025年全球销售额约为2.16亿美元。截至目前，SHR-1918注射液相关项目累计研发投入约24,220万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","BK0196","LU0359201612.USD","LU1997244956.HKD","BK0183","LU2580892862.HKD","01276","LU2495084118.USD","600276","LU0405327148.USD","06978","LU1064130708.USD","LU1655091616.SGD","LU1969619763.USD","LU1328615791.USD","LU0359201885.HKD","BK0188","LU2097828557.USD","LU1820825898.SGD","LU1997245177.USD","LU2580892789.USD","LU1997245094.SGD","BK1574","LU1064131003.USD","LU2097828714.EUR","LU1146622755.USD","BK0012","LU0405327494.USD","LU2097828631.EUR","LU2488822045.USD","159992","LU1023057109.AUD","LU2097828805.USD","LU2543165471.USD","BK1191","LU2289578879.USD","LU1781817850.SGD","LU1580142542.USD","LU2148510915.USD","BK0028","BK1161","LU0359202008.SGD","LU1255011170.USD","LU2328871848.SGD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2611477157","title":"恒瑞医药：不存在按规定应披露而未披露的重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2611477157","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611477157?lang=zh_cn&edition=full","pubTime":"2026-02-13 21:09","pubTimestamp":1770988175,"startTime":"0","endTime":"0","summary":"证券日报网讯2月13日，恒瑞医药在互动平台回答投资者提问时表示，公司日常经营管理和业务状况正常，不存在按规定应披露而未披露的重大信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602133650628369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828714.EUR","LU1328615791.USD","LU1023057109.AUD","BK0183","LU0405327148.USD","LU1820825898.SGD","BK0188","600276","BK0012","LU0359202008.SGD","BK0196","LU1997244956.HKD","LU2097828557.USD","LU1580142542.USD","BK0028","LU1781817850.SGD","01276","LU2148510915.USD","BK1191","LU0359201885.HKD","LU0359201612.USD","LU2328871848.SGD","BK0060","LU2543165471.USD","LU1064131003.USD","LU1997245094.SGD","LU1064130708.USD","LU0405327494.USD","LU2097828805.USD","LU1255011170.USD","LU2580892789.USD","BK0239","LU1969619763.USD","LU2097828631.EUR","LU2488822045.USD","LU2289578879.USD","LU1997245177.USD","LU1146622755.USD","LU2580892862.HKD","LU2097828474.EUR","LU1655091616.SGD","LU2495084118.USD"],"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0060","LU1146622755.USD","600276","LU1655091616.SGD","LU1969619763.USD","LU1580142542.USD","LU1997244956.HKD","601607","LU1064130708.USD","301075","BK0183","LU1328615791.USD","BK0209","300683","LU1781817850.SGD","LU0405327148.USD","LU2097828714.EUR","300142","LU2097828805.USD","BK0028","BK0184","LU1064131003.USD","LU2097828557.USD","BK0070","LU2148510915.USD","LU2289578879.USD","BK0188","BK0077","LU1997245177.USD","LU1997245094.SGD","BK0046","BK0097","LU2097828474.EUR","LU1255011170.USD","LU2580892862.HKD","LU2097828631.EUR","LU2580892789.USD","LU2488822045.USD","BK0239","LU0405327494.USD","BK0012","BK0187","LU2328871848.SGD","LU2495084118.USD","BK0020","BK0099","BK0196","LU1820825898.SGD"],"gpt_icon":0},{"id":"2610993166","title":"恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2610993166","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610993166?lang=zh_cn&edition=full","pubTime":"2026-02-11 19:37","pubTimestamp":1770809832,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113648077695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997244956.HKD","LU1580142542.USD","01276","LU1655091616.SGD","LU1997245177.USD","LU0359201612.USD","LU0359202008.SGD","06978","LU1969619763.USD","LU2580892862.HKD","LU2097828805.USD","LU2097828557.USD","LU2328871848.SGD","BK1574","LU1328615791.USD","LU0405327148.USD","BK1161","159992","LU2488822045.USD","LU1820825898.SGD","LU2097828631.EUR","BK0060","BK0188","LU0359201885.HKD","LU1255011170.USD","LU1781817850.SGD","LU1064130708.USD","LU2097828714.EUR","LU2543165471.USD","LU2580892789.USD","LU1064131003.USD","LU1146622755.USD","BK0239","LU2148510915.USD","LU2289578879.USD","LU1023057109.AUD","LU1997245094.SGD","LU0405327494.USD","BK0183","BK0196","BK0012","600276","BK0028","LU2097828474.EUR","LU2495084118.USD","BK1191"],"gpt_icon":0},{"id":"2610544938","title":"恒瑞医药：公司2025年利润分配方案尚未披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2610544938","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610544938?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:35","pubTimestamp":1770802536,"startTime":"0","endTime":"0","summary":"证券日报网讯2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司2025年利润分配方案尚未披露，敬请关注公司后续于交易所网站上发布的相关公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113647979496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU1064130708.USD","01276","LU1146622755.USD","LU2328871848.SGD","LU2488822045.USD","LU2580892789.USD","BK0028","LU2097828714.EUR","BK0060","LU2580892862.HKD","LU0359201612.USD","BK0183","BK0239","LU1969619763.USD","LU2097828557.USD","BK0196","LU0359202008.SGD","LU1781817850.SGD","LU1997245177.USD","LU1023057109.AUD","BK1191","LU0405327494.USD","BK0012","LU0359201885.HKD","LU2097828631.EUR","LU2495084118.USD","600276","BK0188","LU1580142542.USD","LU1655091616.SGD","LU1328615791.USD","LU1997245094.SGD","LU1820825898.SGD","LU2097828805.USD","LU2148510915.USD","LU2289578879.USD","LU2097828474.EUR","LU0405327148.USD","LU1997244956.HKD","LU2543165471.USD","LU1255011170.USD"],"gpt_icon":0},{"id":"2610647773","title":"恒瑞医药(01276)：注射用瑞康曲妥珠单抗上市许可申请获受理并纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610647773?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:36","pubTimestamp":1770726994,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。研究结果显示，与标准治疗方案相比，瑞康曲妥珠单抗能显著延长HER2 阳性晚期结直肠癌患者的PFS，降低疾病进展或死亡风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","BK0239","LU1064131003.USD","BK0060","LU1655091616.SGD","LU2097828631.EUR","LU2097828805.USD","LU2148510915.USD","BK0183","LU1820825898.SGD","LU1023057109.AUD","LU1146622755.USD","LU2097828474.EUR","600276","LU0405327494.USD","LU0359202008.SGD","LU2543165471.USD","01276","LU1255011170.USD","LU2495084118.USD","LU1328615791.USD","LU2580892862.HKD","BK0188","LU2328871848.SGD","LU1064130708.USD","LU1969619763.USD","LU1997244956.HKD","LU2580892789.USD","LU0359201885.HKD","LU1781817850.SGD","BK0196","LU0405327148.USD","LU1997245094.SGD","LU2097828557.USD","LU2488822045.USD","BK1191","LU0359201612.USD","BK0028","LU2097828714.EUR","LU2289578879.USD","BK0012","LU1997245177.USD"],"gpt_icon":0},{"id":"1190663427","title":"凯莱拉疗法：口服利鲁肽中国二期试验26周平均减重达12.1% 未现平台期","url":"https://stock-news.laohu8.com/highlight/detail?id=1190663427","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190663427?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:00","pubTimestamp":1770724814,"startTime":"0","endTime":"0","summary":"在针对口服利鲁肽（Ribupatide）展开的中国二期临床试验中，凯莱拉疗法（Kailera Therapeutics）披露了令人振奋的进展。数据显示，经过26周的治疗周期，受试者实现了最高达12.1%的平均体重下降。尤为关键的是，研究结果并未观察到减重效果进入平台期的迹象，暗示该疗法的持续有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1655091616.SGD","LU2148510915.USD","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","LU0405327494.USD","LU1328615791.USD","LU1997244956.HKD","LU2289578879.USD","LU0405327148.USD","LU1064131003.USD","LU1064130708.USD","BK0060","LU1997245094.SGD","LU2097828714.EUR","BK0188","LU1781817850.SGD","LU1580142542.USD","LU1997245177.USD","BK0196","LU1255011170.USD","LU2097828805.USD","BK0239","LU1146622755.USD","LU2097828631.EUR","LU2097828557.USD","LU2488822045.USD","BK0183","BK0028","LU1820825898.SGD","BK0012","LU2097828474.EUR","LU2328871848.SGD","LU2495084118.USD","600276"],"gpt_icon":0},{"id":"1199424521","title":"恒瑞医药与Kailera Therapeutics公布口服Ribupatide二期肥胖症试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1199424521","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199424521?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:00","pubTimestamp":1770724813,"startTime":"0","endTime":"0","summary":"恒瑞医药与Kailera Therapeutics公司近日联合宣布，其合作开发的口服药物Ribupatide在针对肥胖症的二期临床试验中取得了积极的顶线结果。\n该试验数据表明，Ribupatide在主要疗效终点上表现出显著优势，达到了预设的统计学标准。这一积极进展为后续的临床开发计划奠定了坚实基础，有望为肥胖症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU1064131003.USD","LU2580892789.USD","LU2097828805.USD","LU2148510915.USD","LU2328871848.SGD","LU1820825898.SGD","LU0405327494.USD","BK0239","LU1997245094.SGD","BK0012","LU1255011170.USD","LU1781817850.SGD","LU2488822045.USD","LU1997245177.USD","LU1146622755.USD","LU2097828631.EUR","LU2097828714.EUR","LU1997244956.HKD","LU0405327148.USD","LU2495084118.USD","LU1969619763.USD","LU2097828474.EUR","LU1655091616.SGD","LU2289578879.USD","BK0028","LU2580892862.HKD","600276","LU2097828557.USD","LU1328615791.USD","BK0060","BK0196","LU1064130708.USD","BK0188","LU1580142542.USD"],"gpt_icon":0},{"id":"2609420569","title":"恒瑞医药(600276.SH)：HRS-4642注射液纳入突破性治疗品种名单 目前国内外尚无同类药物获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609420569","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609420569?lang=zh_cn&edition=full","pubTime":"2026-02-06 17:47","pubTimestamp":1770371265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公告，近日，公司的HRS-4642注射液被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，胰腺癌是一种常见的消化道恶性肿瘤。最新全球癌症统计数据显示，2022年全球胰腺癌新发病例为510,566例，居恶性肿瘤发病第12位;死亡病例为467,005例，居恶性肿瘤发病第6位，约占全球癌症死亡人数的5%。HRS-4642注射液是公司自主研发的KRAS G12D抑制剂，为脂质体剂型。经查询，目前国内外尚无同类药物获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU0359202008.SGD","LU1328615791.USD","LU1781817850.SGD","LU0359201885.HKD","LU2543165471.USD","BK0060","LU1969619763.USD","LU2289578879.USD","01276","BK0188","BK0012","LU1064131003.USD","LU1997244956.HKD","LU2097828714.EUR","LU2328871848.SGD","LU0359201612.USD","LU2148510915.USD","LU1255011170.USD","LU0405327148.USD","LU2097828805.USD","BK0183","BK0028","LU1997245177.USD","LU1146622755.USD","LU1655091616.SGD","LU2097828557.USD","LU2097828631.EUR","LU0405327494.USD","LU1023057109.AUD","LU2580892789.USD","LU2488822045.USD","BK0239","BK1191","BK0196","LU2097828474.EUR","LU2495084118.USD","LU2580892862.HKD","LU1997245094.SGD","LU1064130708.USD","LU1580142542.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2609327389","title":"恒瑞医药子公司获批SHR-1894注射液临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2609327389","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609327389?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:53","pubTimestamp":1770281616,"startTime":"0","endTime":"0","summary":"2月5日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-1894注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物是公司自主研发的治疗用生物制品，预期可在特应性皮炎治疗中发挥保护皮肤屏障和抑制炎症的作用。目前国内外尚无同类药物获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642799628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1655091616.SGD","LU1255011170.USD","LU2097828714.EUR","LU2097828805.USD","LU2495084118.USD","LU1580142542.USD","LU2097828631.EUR","LU0405327494.USD","LU2097828474.EUR","BK0183","600276","BK0239","BK1191","LU1997245177.USD","LU2488822045.USD","LU1023057109.AUD","BK0060","LU2543165471.USD","LU2148510915.USD","LU2580892789.USD","LU0359201612.USD","LU1064131003.USD","LU1969619763.USD","LU2289578879.USD","BK0196","LU0359202008.SGD","LU1146622755.USD","LU2328871848.SGD","BK0188","01276","LU1781817850.SGD","BK0012","LU1064130708.USD","LU0405327148.USD","LU1997244956.HKD","LU0359201885.HKD","LU1997245094.SGD","BK0028","LU2097828557.USD","LU1820825898.SGD","LU2580892862.HKD"],"gpt_icon":0},{"id":"2609834341","title":"港股恒瑞医药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609834341","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609834341?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:30","pubTimestamp":1770262239,"startTime":"0","endTime":"0","summary":"每经AI快讯，恒瑞医药(01276.HK)涨超3%，截至发稿，涨3%，报68.75港元，成交额7126.63万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642588111.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642588111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","BK0239","LU0359202008.SGD","VT","LU1255011170.USD","VXUS","LU2289578879.USD","BK0196","BK0188","LU1820825898.SGD","LU2097828805.USD","BK1191","LU0405327148.USD","BK0012","LU2097828474.EUR","LU2488822045.USD","LU1781817850.SGD","600276","01276","BK0028","LU2495084118.USD","LU1997245094.SGD","LU2097828557.USD","LU0359201612.USD","BK0060","LU2097828631.EUR","LU2148510915.USD","LU1146622755.USD","LU1064131003.USD","LU2543165471.USD","LU1023057109.AUD","LU2580892862.HKD","LU1580142542.USD","BK4588","LU2097828714.EUR","LU2328871848.SGD","LU1969619763.USD","LU0359201885.HKD","LU1997245177.USD","LU0405327494.USD","LU1997244956.HKD","BK0183","BK4585","LU1064130708.USD","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2608351186","title":"恒瑞医药(01276)2月4日斥资931.7万元回购16.5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351186","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351186?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:46","pubTimestamp":1770194772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年2月4日，该公司斥资931.7万元回购16.5万股A股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1064131003.USD","LU0359201885.HKD","LU0405327148.USD","LU2097828631.EUR","LU1655091616.SGD","BK0183","LU2097828474.EUR","159982","LU2097828714.EUR","LU2289578879.USD","399300","LU1064130708.USD","LU1023057109.AUD","BK0188","LU1969619763.USD","LU1255011170.USD","LU1997244956.HKD","LU2495084118.USD","LU2097828805.USD","LU2543165471.USD","LU2580892862.HKD","LU2488822045.USD","LU1781817850.SGD","LU1328615791.USD","LU0405327494.USD","LU1997245094.SGD","BK0012","LU2580892789.USD","LU1820825898.SGD","LU2097828557.USD","LU1146622755.USD","LU0359202008.SGD","BK1191","LU1997245177.USD","01276","LU1580142542.USD","BK0239","BK0028","LU2328871848.SGD","LU2148510915.USD","BK0060","LU0359201612.USD","600276","BK0196"],"gpt_icon":0},{"id":"2608336199","title":"司美格鲁肽年销361亿美元，全球“药王”之战进入下半场","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336199","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608336199?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:43","pubTimestamp":1770176580,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛报道2月3日，诺和诺德发布2025年财报。数据显示，诺和诺德全年营收3090.64亿丹麦克朗(约合489亿美元)，同比增长6%，净利润1024.34亿丹麦克朗(约合162亿美元)，同比 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20260204/c674539713.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260204/c674539713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2328871848.SGD","BK0209","000963","LU2580892789.USD","LU1781817850.SGD","LU2495084118.USD","LU1064130708.USD","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1655091616.SGD","LU2097828557.USD","LU2097828631.EUR","BK0132","BK0239","LU2097828474.EUR","BK0183","LU1820825898.SGD","LU2097828714.EUR","BK0187","LU1255011170.USD","LU1997245177.USD","LU1064131003.USD","BK0028","BK0188","LU0405327494.USD","BK0060","LU2097828805.USD","LU1997244956.HKD","LU1997245094.SGD","LU2289578879.USD","BK0012","BK0175","600276","LU2580892862.HKD","LU1146622755.USD","LU1580142542.USD","LU2148510915.USD","LU1969619763.USD","BK0196"],"gpt_icon":1},{"id":"2608872130","title":"恒瑞医药：公司日常经营管理和业务状况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872130","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608872130?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:07","pubTimestamp":1770127673,"startTime":"0","endTime":"0","summary":"证券日报网讯2月3日，恒瑞医药在互动平台回答投资者提问时表示，公司日常经营管理和业务状况正常，不存在按规定应披露而未披露的重大信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640420282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","LU1064131003.USD","LU0359201612.USD","LU2097828474.EUR","LU0359201885.HKD","LU1820825898.SGD","LU2328871848.SGD","LU1064130708.USD","LU1580142542.USD","600276","BK0060","LU1969619763.USD","LU2097828557.USD","LU1255011170.USD","LU2580892789.USD","LU0405327148.USD","LU1023057109.AUD","01276","LU1997245177.USD","LU2580892862.HKD","LU2097828631.EUR","LU2488822045.USD","LU1328615791.USD","LU2543165471.USD","BK0239","LU2097828714.EUR","LU2148510915.USD","LU1655091616.SGD","LU2289578879.USD","BK1191","BK0028","BK0188","LU1781817850.SGD","BK0183","LU0359202008.SGD","LU1146622755.USD","LU1997245094.SGD","LU2097828805.USD","BK0196","LU1997244956.HKD","LU0405327494.USD","LU2495084118.USD"],"gpt_icon":0},{"id":"2608287131","title":"恒瑞医药：重新提交注射用卡瑞利珠单抗联合方案获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608287131","media":"财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608287131?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:46","pubTimestamp":1770122760,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药发布公告称，公司收到美国食品药品监督管理局的《确认函》，公司重新提交的注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请获得FDA受理。国内也有多款同类产品获批上市。经查询EvaluatePharma数据库，2024年抗PD-1抗体全球销售额合计约为415.46亿美元。截至目前，注射用卡瑞利珠单抗相关项目累计研发投入约为319,740万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-03/doc-inhkpzpf7190703.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-03/doc-inhkpzpf7190703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","01276","LU2580892789.USD","LU0405327148.USD","BK0188","BK0196","BK1191","LU2148510915.USD","LU2097828557.USD","LU1997244956.HKD","LU2580892862.HKD","LU2097828474.EUR","LU2097828631.EUR","LU1580142542.USD","LU1997245177.USD","LU1997245094.SGD","LU1655091616.SGD","600276","LU2328871848.SGD","LU0359202008.SGD","LU0405327494.USD","LU1255011170.USD","LU1328615791.USD","LU2543165471.USD","BK0012","LU2289578879.USD","LU1781817850.SGD","LU1146622755.USD","LU1064130708.USD","LU2097828714.EUR","BK0239","BK0028","LU0359201612.USD","LU2097828805.USD","LU2495084118.USD","LU2488822045.USD","LU1969619763.USD","LU1064131003.USD","LU0359201885.HKD","LU1023057109.AUD","BK0060","LU1820825898.SGD"],"gpt_icon":0},{"id":"2608854966","title":"恒瑞医药回购979万股 金额6.46亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854966","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854966?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:00","pubTimestamp":1770022804,"startTime":"0","endTime":"0","summary":"2月2日，恒瑞医药（600276/01276）发布公告，截至2026年1月31日，公司已回购979万股，占总股本的0.15%，回购资金总额为6.46亿元，回购价格区间为56.1元/股至70元/股。2025年前三季度，恒瑞医药实现收入231.88亿元，归母净利润57.51亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638729383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","LU2543165471.USD","LU0359202008.SGD","LU0359201612.USD","LU2580892789.USD","BK1191","LU1781817850.SGD","LU2495084118.USD","LU1064130708.USD","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1655091616.SGD","LU2097828557.USD","LU2097828631.EUR","BK0239","LU2097828474.EUR","LU1023057109.AUD","BK0183","LU1820825898.SGD","LU2097828714.EUR","LU1255011170.USD","LU1997245177.USD","LU1064131003.USD","BK0028","BK0188","LU0405327494.USD","BK0060","01276","LU2097828805.USD","LU1997244956.HKD","LU1997245094.SGD","LU2289578879.USD","BK0012","LU0359201885.HKD","600276","LU2580892862.HKD","LU1146622755.USD","LU1580142542.USD","LU2148510915.USD","LU1969619763.USD","BK0196"],"gpt_icon":0},{"id":"2608859435","title":"恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608859435","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608859435?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:35","pubTimestamp":1770021352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，公司收到美国食品药品监督管理局(简称“FDA”)的《确认函》，公司重新提交的注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请(简称“BLA”)获得FDA受理。根据《处方药用户付费法案(PDUFA)》，FDA对注射用卡瑞利珠单抗的目标审评日期为2026年7月23日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327148.USD","LU1023057109.AUD","LU2148510915.USD","LU1255011170.USD","LU1655091616.SGD","LU1969619763.USD","LU2097828805.USD","BK0188","BK0012","BK0196","LU2543165471.USD","LU1146622755.USD","LU1997245177.USD","LU0405327494.USD","LU2097828631.EUR","LU1064131003.USD","BK0183","BK0028","LU1328615791.USD","LU2580892862.HKD","LU2097828557.USD","600276","LU0359202008.SGD","01276","BK0239","LU1580142542.USD","LU1820825898.SGD","BK0060","LU0359201885.HKD","LU1781817850.SGD","LU2289578879.USD","LU1997245094.SGD","LU2495084118.USD","LU2580892789.USD","LU2097828714.EUR","BK1191","LU2097828474.EUR","LU1997244956.HKD","LU0359201612.USD","LU2328871848.SGD","LU2488822045.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2607078996","title":"江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078996","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078996?lang=zh_cn&edition=full","pubTime":"2026-01-31 09:12","pubTimestamp":1769821922,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司于2026年1月30日披露了翌日披露报表，报告了其股份变动及回购情况。根据公告，公司于2026年1月30日通过上海证券交易所交易系统以集中竞价交易方式回购了343,100股A股股份，占公司总股本的约0.0054%。此次回购的每股最高价格为人民币58.21元，每股最低价格为人民币58.12元，支付的总金额为人民币19,959,865元。 公告明确，本次回购的股份将全部用于公司A股员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1997245094.SGD","LU1781817850.SGD","LU2097828557.USD","600276","LU2097828474.EUR","159982","BK0183","01276","LU1255011170.USD","399300","LU1997244956.HKD","LU1655091616.SGD","LU2097828805.USD","BK0028","LU1064131003.USD","LU2580892862.HKD","LU2495084118.USD","LU1820825898.SGD","LU1997245177.USD","LU1328615791.USD","BK0188","BK0196","LU2097828714.EUR","LU1064130708.USD","BK0060","BK1191","LU0359202008.SGD","LU0405327148.USD","LU1023057109.AUD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU2580892789.USD","BK0012","LU0405327494.USD","LU2488822045.USD","LU2097828631.EUR","LU2543165471.USD","LU2289578879.USD","LU1969619763.USD","LU1580142542.USD","LU1146622755.USD","LU0359201612.USD","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772174391617,"stockEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.0084},{"period":"3month","weight":-0.0863},{"period":"6month","weight":-0.1436},{"period":"1year","weight":0.1972},{"period":"ytd","weight":-0.0478}],"compareEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0448}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"397246人(较上一季度增加8.94%)","perCapita":"16058股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}